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AbstrACt
Introduction The European Prevention of Alzheimer’s 
Dementia (EPAD) project is funded initially by the 
Innovative Medicines Initiative and has been established to 
overcome the major hurdles hampering drug development 
for secondary prevention of Alzheimer’s dementia, by 
conducting the EPAD Longitudinal Cohort Study (LCS) 
in alignment with the Bayesian adaptive designed EPAD 
Proof-of-Concept (PoC) trial.
Methods and analysis EPAD LCS is an ongoing 
prospective, multicentre, pan-European longitudinal 
cohort study. Participants are recruited mainly from 
existing parent cohorts across Europe to form a 
‘probability-spectrum’ population covering the entire 
continuum of anticipated probability for Alzheimer’s 
dementia development. The primary objective of the 
EPAD LCS is to be a readiness cohort for the EPAD PoC 
trial though a second major objective is to generate a 
comprehensive and large data set for disease modelling 
of preclinical and prodromal Alzheimer’s disease. This 
characterisation of cognitive, biomarker and risk factor 
(genetic and environmental) status of research participants 
over time will provide the necessary well-phenotyped 
population for developing accurate longitudinal models for 
Alzheimer’s disease covering the entire disease course 
and concurrently create a pool of highly characterised 
individuals for the EPAD PoC trial.
Ethics and dissemination The study has received the 
relevant approvals from numerous Institutional Review 
Boards across Europe. Findings will be disseminated 
to several target audiences, including the scientific 
community, research participants, patient community, 
general public, industry, regulatory authorities and 
policy-makers. Regular and coordinated releases of 
EPAD LCS data will be made available for analysis to 
help researchers improve their understanding of early 
Alzheimer’s disease stages and facilitate collaborations.
trial registration number NCT02804789.
IntroduCtIon 
Alzheimer’s disease (AD) is the leading cause 
of dementia globally.1 As the population ages, 
the number of people with dementia will 
rise, and the economic burden of AD will 
increase dramatically from an already high 
baseline (~€262 billion in 2015).2 Clinical 
trials targeting populations with manifest 
dementia have so far failed.3 There is now 
consensus that the genesis of AD predates 
dementia onset by over 20 years,4 presenting 
an opportunity for early disease course modi-
fication. The key challenge is to accurately 
identify individuals with a high probability of 
subsequent AD dementia development, who 
are suitable for trial inclusion and willing to 
participate in secondary prevention studies. 
Secondary prevention populations can have, 
for example, evidence of AD pathology 
through relevant biomarker abnormalities, 
but without a clinical diagnosis of dementia.5 
Current proposals for defining an individ-
ual’s probability for dementia development 
have focused mainly on the AD stage prox-
imal to dementia onset and have relied on a 
very limited number of factors, for example, 
cognition and amyloid or tau biomarkers.6–10 
Disease models and their phenotypic expres-
sion needed for probability estimation in 
earlier disease stages are currently less well 
defined. It is important to first develop accu-
rate disease models for dementia onset or 
AD progression in early, asymptomatic or 
strengths and limitations of this study
 ► Prospective, multicentre, pan-European longitudi-
nal cohort study with a large sample size recruited 
mainly from existing parent cohorts.
 ► Well-phenotyped ‘probability-spectrum’ population 
covering the entire continuum of probability for 
Alzheimer dementia development.
 ► Disease modelling based on four dimensions includ-
ing cognitive and other clinical features, biomarkers, 
risk factors (fixed and modifiable) and trajectories of 
change in these over time.
 ► Readiness population for a Bayesian adaptive de-
signed proof-of-concept trial, with high-quality run-
in, pre-randomisation data against which the impact 
of various interventions will be measured.
 ► Limitations: alignment of the cohort with the proof-
of-concept trial means that this is not a traditional 
epidemiologically selected real-life population.
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mildly symptomatic disease stages. These people need 
to be followed up longitudinally, after which they could 
be recruited into trials designed to reduce early disease 
burden and therein decrease the probability of devel-
oping dementia. Moreover, the refined definition of 
populations at risk of dementia will provide data for the 
optimal stratification of these populations to match onto 
tailored disease-modifying therapies as the basis for better 
personalised medicine.11
The European Prevention of Alzheimer’s Dementia 
(EPAD) is a project to develop an environment for and 
then test multiple different interventions targeting 
the secondary prevention of AD dementia.5 The EPAD 
project is ongoing across Europe with 38 partners from 
academia and the commercial sector. EPAD is conducting 
a Longitudinal Cohort Study (EPAD LCS) in alignment 
with a Bayesian adaptive designed EPAD Proof-of-Con-
cept (PoC) trial (figure 1). This article presents the EPAD 
LCS study protocol.
objECtIvEs of EPAd LCs
EPAD LCS is a prospective, multicentre, pan-European 
cohort study that will address the dual need to develop 
accurate longitudinal models for AD covering the entire 
disease course and to create a pool of highly character-
ised individuals for potential recruitment into the EPAD 
PoC trial. EPAD LCS will have a well-phenotyped ‘prob-
ability-spectrum’ population, that is, covering the entire 
continuum of probability for dementia development, 
from low to high and everywhere in between.
EPAD LCS has four main objectives:
1. To provide a well-phenotyped population (readiness 
population) for the EPAD PoC trial to minimise trial 
screening failures.
2. To provide a well-phenotyped probability-spectrum 
population for developing and continuously improv-
ing disease models for AD in individuals without de-
mentia. Probability for subsequent dementia will con-
sider four different dimensions: cognitive and other 
clinical features, biomarkers, risk factors (fixed and 
modifiable) and trajectories of change in these over 
time.
3. To use disease models for assessing where and why 
participants fall in the overall probability continuum, 
and thereafter inform selection of participants into the 
EPAD PoC trial.
4. To provide high-quality run-in, pre-randomisation data 
for the EPAD PoC trial against which the impact of var-
ious interventions is measured.
EPAd LCs study dEsIgn And MEthods
recruitment sources for EPAd LCs
EPAD LCS participants will be recruited mainly from 
existing parent cohorts (PCs) across Europe. These can 
be research cohorts (eg, observational studies with partic-
ipants from the general population or other populations, 
Figure 1 Flow of participants to European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS) and into 
the EPAD Proof-of-Concept (PoC) trial.
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prevention trials, or pre-existing readiness cohorts) or 
clinical/routine care cohorts (memory clinic or general 
practitioner/primary care based). Cohort eligibility 
criteria are active cohorts including participants without 
dementia aged at least 50 years; willingness of the prin-
cipal investigator of the PC to provide research partici-
pants for EPAD LCS and EPAD PoC trial; and existing 
consent from participants for re-contact by Parent Cohort 
team, or possibility to obtain consent to re-contact by PC 
team.
To ensure PC engagement, they will be selected based 
on close connections with core partners in the EPAD 
Consortium, maximally leveraging those involved in 
European Medical Information Framework (EMIF) 
and regional initiatives like the Dementias Platform UK 
(DPUK). Many other cohorts will also be included as 
needed.
Recruitment from existing PCs will be complemented 
with participants coming directly from clinical settings 
without a PC.
The involvement of existing PCs and clinics where 
some data are already available on potential participants 
will facilitate fast recruitment. In addition, the variety 
of recruitment sources (from general populations to 
memory clinics) will provide a probability-spectrum 
population covering the entire continuum of probability 
for AD dementia development.
EPAd LCs study population
EPAD LCS eligibility and exclusion criteria are listed in 
table 1.
EPAD LCS will be maintained over time by continuous 
refilling from the PCs or clinical settings as participants 
move into the PoC trial or drop out. Initial duration of 
EPAD LCS will be from May 2016 (start of recruitment) 
to December 2019 (end of current Innovative Medi-
cines Initiative (IMI) funding), and after that extension 
of consent will be asked from participants who are still 
eligible for EPAD LCS. EPAD LCS participants will not be 
asked to leave their PCs. Participants recruited into the 
EPAD PoC trial may return to EPAD LCS at least 30 days 
after trial completion, if they wish to and if they are still 
eligible for EPAD LCS.
The current status of the LCS can be followed on 
the EPAD website (http:// ep- ad. org/) where updates 
are continuously posted as new research participants, 
recruiting sites and countries join the project. There are 
now over 1000 participants from 21 active sites in seven 
countries. Recruitment status as of 29 November 2018 
is shown in figure 2. Recruitment rate is expected to 
increase as recently opened sites reach their full capacity 
and new sites/countries also start recruiting.
EPAd LCs participant selection process
Selection from PCs (PrePAD)
Potential EPAD LCS research participants will be identi-
fied by each PC team based on data in their own PC. Indi-
vidual-level PC data do not have to be shared with EPAD. 
To ease the search process, a data discovery software tool 
is provided to PCs by EPAD. The Participant Register for 
EPAD (PrePAD) solution has been developed by EPAD 
study partners working with EMIF and DPUK.12 PrePAD 
queries will be run that provide counts of participants, 
without giving EPAD LCS access to individual-level data. 
Only the PC team will be able to identify the selected 
PC research participants and contact them. Those who 
express interest in EPAD LCS participation are then 
referred to the local LCS site.
As of March 2018, 10 different cohorts with a total of 
17 500 participants aged >50 years and without dementia 
have been included in PrePAD.12 New cohorts are contin-
uously added.
Selection from clinical settings (PrePAD Velocity)
The participant or referring clinician will contact the 
local EPAD LCS site directly. The referring clinician will 
verify eligibility using a checklist based on assessments 
available in each referring clinical setting.
Novel flexible approach to selection
EPAD LCS will provide a probability-spectrum popu-
lation, that is, where the entire continuum from low to 
high probability of subsequent dementia is represented 
at any time during the study. Probability of developing 
dementia is determined by multiple dimensions, for 
example, cognition, biomarkers and traditional risk 
factors (genetic and environmental). However, no disease 
model covering all these dimensions is currently available 
to determine where an individual is located on the prob-
ability continuum. In addition, an individual may move 
across the continuum over time due to changes in these 
dimensions.
EPAD LCS needs to ensure that at any time (1) the 
entire probability continuum is represented, and (2) 
there are enough participants potentially eligible 
for an adaptive designed trial, where multiple active 
experimental drugs may be assessed concurrently with 
a shared placebo arm, and interim analyses may affect 
participant accrual or stopping/continuing trial arms. 
For this purpose, a flexible approach to selection will 
be used (box 1). This will allow for adjustments over 
time as data accumulate, disease models improve and 
the needs of the EPAD PoC trial’s intervention pipe-
line change.
To guarantee a well-organised selection process, EPAD 
LCS has a Balancing Committee (biostatisticians, data 
managers and LCS senior investigators) responsible for 
data monitoring and algorithm adaptations, and an Algo-
rithm Running Committee responsible for algorithm 
documenting, and sending outputs to PCs or clinics in 
PrePAD Velocity.13
This centralised selection process was also set up 
because investigators will be blinded to results of new data 
collected in the EPAD LCS, namely cerebrospinal fluid 
(CSF) biomarkers of tau and amyloid, imaging results 
and apolipoprotein E (APOE) ε4 allele carrier status, 
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to limit biases in clinical assessments that may affect 
disease modelling work in EPAD LCS. This blinding is 
only compromised if a research participant enters LCS 
via PrePAD Velocity with known and disclosed biomarker 
status or if the research participant enters an arm of 
the EPAD PoC which requires only biomarker-positive 
individuals.
EPAd LCs outcomes and other assessments
EPAD LCS outcomes, other assessments and the data 
collection schedule are detailed in tables 2 and 3. The 
assessments are based on recommendations devel-
oped by the five EPAD Scientific Advisory Groups 
(SAGs) (Clinical and Cognitive Outcomes, Epidemi-
ology, Fluid Biomarkers, Genetics and Imaging). SAGs 
Table 1 Criteria for selection of European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS) 
participants
Eligibility 
criteria
 ► Age at least 50 years
 ► Completing all EPAD LCS screening/baseline assessments
 ► Able to read and write and with minimum 7 years of formal education
 ► Willing in principle to participate in the EPAD Proof-of-Concept trial subject to further informed consent
 ► Have a study partner or can identify someone willing in principle to be a study partner*
Exclusion 
criteria
 ► Research participants who fulfil diagnostic criteria for any type of dementia (eg, NINCDS-ADRDA for AD; Lund 
Criteria for FTD, McKeith Criteria for DLB, NINCDS-AIREN Criteria for Vascular Dementia)
 ► CDR≥1
 ► Known carriers of a PSEN1, PSEN2 or APP mutation associated with Autosomal Dominant AD or any other 
neurodegenerative disease
 ► Presence of any neurological, psychiatric or medical conditions associated with a long-term risk of significant 
cognitive impairment or dementia including but not limited to pre-manifest Huntington’s disease, multiple 
sclerosis, Parkinson’s disease, Down syndrome and active alcohol/drug abuse; or major psychiatric disorders 
including current major depressive disorder, schizophrenia, schizoaffective or bipolar disorder.
 ► Any cancer or history of cancer in the preceding 5 years (excluding cutaneous basal or squamous cell cancer 
resolved by excision)
 ► Any current medical conditions that are clinically significant and might make the subject’s participation in 
an investigational trial unsafe, for example, uncontrolled or unstable disease of any major organ system; 
history within the last 6 months of any acute illness of a major organ system requiring emergency care or 
hospitalisation, including revascularisation procedures; severe renal or hepatic failure; unstable or poorly 
controlled diabetes mellitus, hypertension or heart failure; malignant neoplasms within the last 3 years (except 
for basal or squamous cell carcinoma in situ of the skin, or localised prostate cancer in men); any clinically 
relevant abnormalities in blood parameters included in local routine assessments; severe loss of vision, 
hearing or communicative ability; or any conditions preventing co-operation or completion of the required 
assessments in the trial, as judged by the investigator
 ► Any contraindications for MRI/PET scan
 ► Any contraindications for lumbar puncture
 ► Any evidence of intracranial pathology which, in the opinion of the investigator, may affect cognition including 
but not limited to brain tumours (benign or malignant), aneurysm or arteriovenous malformations, territorial 
stroke (excluding smaller watershed strokes), recent haemorrhage (parenchymal or subdural) or obstructive 
hydrocephalus. Research participants with a MRI scan demonstrating markers of small vessel disease (eg, 
white matter changes or lacunar infarcts) judged to be clinically insignificant, or microbleeds are allowed
 ► Participation in a Clinical Trial of an Investigational Product (CTIMP) in the last 30 days (continued participation 
in the parent cohort is expected). Participation in a non-CTIMP is not an exclusion criterion
 ► Diminished decision-making capacity/not capable of consenting at the screening or 6-month visit. If at a 
subsequent annual EPAD LCS visit health professionals suspect diminished consent capacity according 
to local routine procedures, a formal assessment of the research participant’s capacity to consent will be 
conducted (eg, University of California, San Diego Brief Assessment of Capacity to Consent). The participant 
will be offered the opportunity to continue in the EPAD LCS under suitable local regulations regarding 
capacitous participants who have consented to enter a longitudinal study who subsequently lose capacity. 
Capacity will be assessed at each study visit using the correct legal framework.
*A study partner is, for example, relative or friend who is at least 18 years old, may or may not live together with the participant, and is 
available either for face-to-face or telephone contact with the EPAD LCS team. As EPAD LCS participants do not have dementia, have no 
or only slight impairment (ie, Clinical Dementia Rating, CDR 0 or 0.5) and are fully capable of providing informed consent (as per exclusion 
criteria), the primary role of the study partner in EPAD LCS will be as informant.
AD, Alzheimer’s disease; APP, amyloid precursor protein; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; NINCDS-
ADRDA, National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association 
(now Alzheimer’s Association); NINCDS-AIREN, National Institute of Neurological Disorders and Stroke–Association Internationale pour la 
Recherché et l’Enseignement en Neurosciences; PSEN, presenilin.
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recommendations were based on reviewing the current 
literature, following widely accepted practices, and 
minimising participant burden.
Cognitive outcomes
The selection process for EPAD LCS cognitive outcome 
measures has been described previously.14 The EPAD 
Neuropsychological Examination (ENE) battery (table 3) 
was chosen to cover all relevant cognitive domains, with 
greatest possible sensitivity to early-stage changes. The 
ENE battery was also developed to be modulable, that is, 
to allow individual components to be selected out corre-
sponding to specific drug targets if necessary during the 
EPAD PoC trial. In addition, component tasks will have 
four alternative forms for retesting.
For LCS purposes, primary outcomes include anchor or 
criterion measure(s) accepted by regulatory authorities 
in previous registration trials. The Repeatable Battery for 
the Assessment of Neuropsychological Status (RBANS) 
will serve as the criterion measure for this study.14 For 
statistical purposes, the RBANS Total Scale Index Score 
(table 3) will serve as the primary outcome. LCS will also 
help validate the secondary and exploratory cognitive 
outcome measures against a known and accepted crite-
rion measure. Although the EPAD LCS is conducted in 
compliance with Good Clinical Practice (GCP), including 
the primary outcome, the computerised secondary and 
exploratory cognitive measures are undergoing addi-
tional validation in EPAD LCS and, thus, do not yet fully 
meet GCP (Title 21 CFR Part 11/European Union Annex 
11).
CSF biomarker outcomes
Measurements will include AD-related markers (beta-am-
yloid, total tau and phosphorylated tau), and these data 
will be used for disease modelling and for staging of 
disease pathology. CSF sampling follows a harmonised 
preclinical protocol and analyses take place using the 
fully automatised Roche Elecsys System in a single labora-
tory (University of Gothenburg). Additional CSF is stored 
in the EPAD BioBank at the Roslin Research Institute, 
University of Edinburgh with all other fluid samples.
Neuroimaging outcomes
The selection process for the neuroimaging measures 
included in the LCS protocol was based on evidence from 
available studies with an emphasis on secondary preven-
tion of AD. Other considerations were usefulness of 
imaging data for the EPAD PoC trial, participant burden, 
implementation and costs, and avoiding redundancies 
between imaging and non-imaging measures.
The MRI acquisition is divided into
1. Core image acquisition, conducted in all LCS partici-
pants to assess study eligibility, for baseline assessment 
that can be used for subsequent safety monitoring in the 
EPAD PoC trial, and for quantitative analysis of brain 
structure and vascular lesions. Alzheimer’s Disease 
Neuroimaging Initiative (ADNI)–like protocols and 
Figure 2 European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS) recruitment status (29 
November 2018). 
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quality control will be used to ascertain precision in 
measuring change.
2. Advanced image acquisition, which only a subset of 
sites with suitable equipment and experience will ac-
quire. This may include one or more of the following 
types of acquisition: 3D susceptibility weighted imag-
ing or 3D-T2*, diffusion tensor imaging, arterial spin 
labelling and resting state functional MRI.
Genetic assessments
The primary genetic assessment will include APOE geno-
type. The samples may also be sequenced when additional 
resources become available. Genetic variants with strong 
effect (eg, APP, PSEN1 and 2) are too rare in the popula-
tion to justify testing in the EPAD LCS. In addition, most 
of these rare mutations are observed in individuals with 
early-onset AD and are therefore unlikely to be included 
in the EPAD LCS.
Other assessments
A broad range of sociodemographic, medical and life-
style-related data will be collected (tables 2 and 3). Mini-
Mental Status Examination15 and Clinical Dementia 
Rating scale16 will be used given their use principally as 
clinical descriptors. Biological samples will include blood, 
urine and saliva (eg, for cortisol measurements) stored 
under optimal conditions in the central EPAD Biobank.
EPAD LCS-MINI protocol for participants who maintain a low 
likelihood of trial inclusion
During EPAD LCS, it may become clear that some partici-
pants maintain a low likelihood of being invited to the PoC 
trial. This may happen for several reasons, for example, 
developing health conditions that preclude trial partici-
pation or showing no impairment/decline in cognition 
and AD biomarkers. Starting from their third visit (1 year 
after baseline), such participants may have the possibility 
to continue with a lower-burden protocol, that is, without 
the yearly MRI and CSF sampling.
Data sources, collection and monitoring
The only data source for this study will be data collected 
as part of the EPAD LCS. Electronic data capture will 
be used as appropriate, for example, for cognitive and 
imaging data. Central laboratories will be used for all CSF 
(University of Gothenburg) and genetic (University of 
Edinburgh) assessments, and central reading of all neuro-
imaging will be undertaken (University of Edinburgh, 
VU University Medical Centre Amsterdam). A common 
pre-analytical procedures schedule for sample collection, 
storage and shipment will be used at all EPAD LCS sites. 
The study will be monitored in accordance with the Inter-
national Conference on Harmonisation (ICH) GCP (ICH 
Topic E6, 1996).
stAtIstICAL AnALysIs
sample size
To achieve our objective of running a platform trial, we 
anticipate needing a readiness cohort of several thou-
sand people, that is, the number will be determined by 
the EPAD PoC trial needs. The EPAD LCS sample size 
will be maintained through continuous recruitment from 
PCs and via PrePAD Velocity. Strategies for motivation 
and engagement as well as improving the research expe-
rience for participants will be developed, including, for 
example, newsletters, websites and telephone contact 
from the study sites.
disease modelling
AD is a complex condition, and an individual’s proba-
bility of developing dementia is most likely the result of 
box 1 novel flexible approach to participant selection
flexible algorithm for identification of potential 
participants from parent cohorts (PCs)
 ► For example, probability of subsequent dementia (and the selection 
algorithm) may be initially based on age, absence of dementia di-
agnosis and family history of Alzheimer’s disease (AD) in a PC with 
less extensive assessments; or age, cognitive performance and 
APOE genotype in another PC with more detailed assessments; or 
age, cognitive performance, MRI and cerebrospinal fluid biomarkers 
in a PC where such data are available.
 ► The Participant Register for EPAD (PrePAD) queries of PCs will be 
conducted potentially every month and may be adjusted depending 
on several factors: types of available data in the PC; the structure 
of the probability spectrum at any given time point in European 
Prevention of Alzheimer’s Dementia Longitudinal Cohort Study 
(EPAD LCS); the EPAD proof-of-concept (PoC) trial’s intervention 
pipeline; the capacity at each EPAD LCS site to baseline and man-
age new participants.
 ► The flexible algorithm will be agreed on and applied by the EPAD 
LCS Balancing Committee, and the output will be provided to each 
PC by the Algorithm Running Committee.
oversampling or undersampling from different types of PCs
 ►  For example, if some PCs are more likely to provide participants 
with a profile suitable for a certain PoC trial arm, oversampling from 
such cohorts and undersampling from others may occur before and 
during the trial recruitment period.
flexible algorithm and oversampling/undersampling for 
PrePAd velocity
 ► For similar reasons, a central element of PrePAD Velocity will be that 
the AD biomarker status of referred patients should be known from 
their regular clinical assessments.
 ► The selection algorithm will be agreed on by the Balancing 
Committee based on information about assessments available in 
each referring clinical setting. The Algorithm Running Committee 
will provide a checklist to the referring clinician for verifying eligibil-
ity before contacting the local EPAD LCS site.
flexible algorithm for refilling EPAd LCs over time
 ► The aforementioned procedures will be applied for both establishing 
and refilling the EPAD LCS.
 ► The structure of the probability spectrum in LCS may change over 
time because participants (1) move into the PoC trial, (2) drop out 
or (3) their characteristics (eg, cognition, biomarkers, risk factors) 
change.
 ► Depending on the structure of the probability spectrum at any given 
time point in LCS, participants coming in may or may not need to 
match participants moving out.
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Table 2 European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study outcomes and other assessments
Primary 
cognitive 
outcome
The RBANS Total Scale Index Score based on:
 ► Verbal Episodic Memory: List Learning and Story Memory
 ► Visual Episodic Memory: Figure Recall
 ► Visuospatial/Constructional: Figure Copy and Line Orientation
 ► Language: Picture Naming
 ► Attention/Executive Functioning: Semantic Fluency, Digit Span, Coding
Secondary 
outcomes
Cognitive outcomes
 ► Working memory: Dot Counting (NIH EXAMINER25 26)
 ► Choice reaction time and set shifting: Flanker (NIH EXAMINER)
 ► Paired associate learning: Favourites (University of California, San Francisco27)
CSF biomarkers
 ► Beta-amyloid, total tau, phosphorylated tau
Neuroimaging outcomes (MRI)
 ► Hippocampal and whole-brain volume
Exploratory 
outcomes
Cognitive outcomes
 ► Allocentric Space: Four Mountains Task (Cambridge University19)
 ► Navigation in Egocentric Space: Virtual Reality Supermarket Trolley (University College London28)
Other clinical outcomes
 ► Amsterdam Instrumental Activities of Daily Living Questionnaire29 30
Neuroimaging outcomes
 ► Multiregion structural MRI analysis
 ► Functional regional and network measures
Other 
assessments
Clinical:
 ► Dementia diagnosed by the participant’s physician, including type and date of diagnosis
 ► MMSE, Mini-Mental State Examination15
 ► CDR, Clinical Dementia Rating Scale16
 ► GDS, 30-item Geriatric Depression Scale31 32
 ► STAI, State-Trait Anxiety Inventory33
 ► Pittsburgh Sleep Quality Index34
 ► Physical examination, including, for example, neurological examination, blood pressure, pulse, weight, 
height and hip–waist circumference measurements
 ► Medical history (yes/no): family history of Alzheimer’s disease (AD) (first-degree relatives), stroke, 
diabetes mellitus (type 1 or 2), hypertension, hypercholesterolemia, myocardial infarction, chronic 
ischaemic heart disease, chronic obstructive pulmonary disease, asthma, depression, rheumatoid 
arthritis, any cancer, general anaesthesia after the age of 50 years, head injury (Brain Injury Screening 
Questionnaire35), mild cognitive impairment, other conditions
 ► Current medication: name of drugs; treatment duration (<1 year/1–5 years/>5 years)
Biomarkers:
 ► Collection of CSF and blood, urine and saliva samples for future biomarker assessments (emerging AD 
biomarkers)
 ► APOE genotype, Polygenic Scores
Other:
 ► Sociodemographics: date of birth, sex, ethnicity, years of formal education, marital status
 ► Lifestyle factors:
 – Smoking (never/past/ current)
 – Alcohol consumption (units/week)
 – Drug abuse/misuse (never/past/ current)
 – Diet (questionnaire, Healthy Ageing through Internet Counselling in the Elderly, HATICE36)
 – Physical activity: leisure-time physical activity that lasts at least 20–30 min and causes 
breathlessness and sweating. Frequency assessed as daily, 2–3 times a week, once a week, 2–3 
times a month, a few times a year or not at all37 38
 – Life events (brief questionnaire based on the Swedish National Study on Ageing and Care, SNAC39)
 – Self-rated health and self-rated fitness (Likert-type questions with response options very good/
good/satisfactory/relatively poor/very poor38)
 ► Handedness
CSF, cerebrospinal fluid; NIH EXAMINER, National Institutes of Health–Executive Abilities: Measures and Instruments for 
Neurobehavioral Evaluation and Research; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status. 
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multiple contributing factors.1 3 In EPAD LCS, partici-
pants may fall on a continuum of overall probability for 
subsequent dementia driven by several underlying dimen-
sions: cognition, AD-related biomarkers, traditional risk 
factors (genetic and environmental) and their longitu-
dinal changes. These dimensions may be continuous in 
nature. Treating them as such rather than dichotomising 
or categorising them may result in substantial gains 
in efficiency and avoidance of information loss when 
deciding where and why a participant falls in the overall 
probability continuum. This is especially important as 
participants with similar overall probability may have 
different contributions from the various dimensions. 
Interrogating the underlying dimensions in addition to 
the overall predicted probability will also facilitate deci-
sions on participant stratification considering the drivers 
and needs related to compounds to be tested in the EPAD 
PoC trial.
Longitudinal modelling of cognitive outcomes, 
biomarkers and risk factors will be used to characterise 
these dimensions dynamically and relate their trajecto-
ries to the probability of AD dementia development or 
other meaningful intermediate disease states. Modelling 
will identify and rank strata of subpopulations of different 
probability. Each subpopulation will have a cognitive, 
biomarker and risk factors profile, and this stratification 
will be used to identify potential interventions, the size 
of a potential intervention effect and to guide the flow of 
participants from EPAD LCS into subsequent arms of the 
PoC trial.
The starting point of the modelling will be mixed-ef-
fects models for the cognitive outcomes, biomarkers 
and risk factors, especially as dementia events are 
expected to be rare in the first few years of follow-up 
of participants. Complexity of investigated models will 
subsequently increase and focus on (multivariate) latent 
trajectory/class mixed models for the longitudinal 
outcomes and biomarkers, survival and more general 
event history models for progression to AD dementia 
and joint models linking these longitudinal outcomes 
and biomarkers to AD dementia. The longitudinal 
models will initially be developed for each cognitive 
outcome and biomarker separately and then combined 
to ultimately maximise the prediction of probability for 
subsequent dementia.
Analyses of cognitive outcomes will be carried out at 
both the individual cognitive domain and composite 
score (RBANS Total Scale Index) levels. Robustness of 
models developed will be evaluated using cross-validation.
As data accrue in the EPAD LCS, soft data locks and 
releases will occur after 500, 1000 and 2000 participants 
(and by intervals of 1000 thereafter) and by stage of 
follow-up, for example, baseline, 1-year, 2-year and 
so on, to inform selection algorithms for EPAD LCS; 
provide updated information for improving selection 
into the EPAD PoC trial; and provide updated disease 
models.
EthICAL AsPECts
The study is conducted in full conformance with the 
principles of the ‘World Medical Association Declaration 
of Helsinki’ (52nd WMA General Assembly, Edinburgh, 
Scotland, October 2000, including the Notes of Clarifica-
tion as added in 2002, Washington, and 2004, Tokyo, and 
2008, Seoul, and 2013, Fortaleza), ICH guidelines for GCP 
and local legislation of the country in which the research 
is conducted, whichever affords the greater protection to 
the individual. EPAD LCS has received ethical approval 
from numerous institutional review boards across Europe.
EPAD has an Ethics Workgroup examining the 
complex ethical considerations involved in the project 
and providing appropriate recommendations.17 18
Informed consent
As the EPAD project is multistaged, staged consent will 
be used as decision-making model.19 Staged consent 
feeds relevant information—bit by bit, extended over 
time—to participants and study partners, and asks 
informed consent at every step when they need to make 
important decisions. Although informed consent is given 
for a specific stage of EPAD (eg, consent for LCS does 
not imply consent for the PoC trial), information about 
the ‘totality of EPAD’ will always and explicitly be made 
available.
Potential disclosure of risk information
Overall estimated probability for developing AD dementia 
will not be disclosed to research participants due to insuf-
ficient accuracy/robustness of current disease models. 
However, findings with established clinical relevance 
and requiring further monitoring and treatment will be 
disclosed to participants, and appropriate measures will 
be taken. AD-related CSF biomarkers may be disclosed 
if progression to AD dementia is suspected during EPAD 
LCS, or where it is considered relevant to an individual’s 
ongoing clinical management, or if a participant is later 
invited to the PoC trial.
Privacy of personal data
EPAD LCS will ensure that data on participants are appro-
priately managed, and participant and study information 
are treated as confidential. All participant study records 
are identified by the participant identification number to 
maintain participants’ confidentiality.
rEsEArCh PArtICIPAnt InvoLvEMEnt
EPAD has established a Research Participants Panel to 
provide feedback of the experience of research partici-
pation, to ensure that participant perspectives are repre-
sented in decision-making about the future of the project 
and to advise local and central EPAD LCS teams. The 
local panel will consist of 6–10 EPAD LCS participants at 
each site and will meet at least twice annually. All EPAD 
LCS participants at a site will be eligible to take part and 
asked to join the panel for 2 years. A waiting list will be 
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maintained of those who are interested if the panel is full. 
One member of the local panel will also be asked to attend 
the EPAD General Assembly, to contribute to discussions 
on study progress, governance and future plans.
dIssEMInAtIon PLAn
Findings will be disseminated to several target audiences, 
including the scientific community, research participants, 
patient community, general public, industry, regulatory 
authorities and policy-makers. Types of communication 
will include scientific publications, conference presenta-
tions, press releases, interviews and other media commu-
nications (including social media), meetings and so on. 
Information and regular updates are posted on the EPAD 
project website ( www. ep- ad. org).
Data collected from EPAD LCS will be made available 
for analysis to help researchers everywhere improve their 
understanding of the early stages of AD and facilitate 
collaborations.
dIsCussIon
The EPAD project has been established to overcome 
the major hurdles hampering drug development for the 
secondary prevention of AD dementia, by conducting 
the EPAD LCS in alignment with the Bayesian adaptive 
designed EPAD PoC trial. This set-up addresses the dual 
need for (1) developing accurate longitudinal models 
for AD covering the entire disease course and (2) devel-
oping an adequate infrastructure for facilitating identi-
fication of participants and clinical trial recruitment. 
While several dementia prediction models have already 
been developed, very few have been validated, and none 
has been tested in a drug trial. The alignment of a longi-
tudinal cohort study with an adaptive trial design within 
the same project5 is a novel approach that closes the 
previous gap between dementia prediction and preven-
tion. This design aspect differentiates EPAD LCS from 
other international networks of observational studies, for 
example, the World Wide ADNI,20 the Integrative Anal-
ysis of Longitudinal Studies of Ageing and Dementia 
(IALSA/Maelstrom),21 or Stroke and Cognition consor-
tium (STROKOG).22 Other novel solutions for facilitating 
trial recruitment include, for example, online Brain 
Health Registers,23 24 but they require older populations 
with significant internet literacy, and outcome measures 
cannot yet be aligned between the online observational 
cohorts and clinical trials.
EPAD LCS recruitment relies on existing cohorts across 
Europe. The variety of recruitment sources, that is, from 
general populations to memory clinics, will ensure that the 
EPAD LCS probability-spectrum population can cover the 
entire continuum of probability for AD dementia devel-
opment. The yearly EPAD LCS follow-up with compre-
hensive cognitive, clinical and biomarker assessments 
will provide a well-phenotyped population, generating 
high-quality data for updating disease models, for easier 
identification of individuals suitable for trial inclusion, 
and for use as trial run-in data and reference for evalu-
ating intervention efficacy. The novel flexible approach 
to participant selection is designed to balance the disease 
modelling and adaptive trial design needs. Both EPAD 
LCS and EPAD PoC trial will be run in an exclusive 
network of highly selected, expert sites (Trial Delivery 
Centres) selected on the basis of strictly applied criteria 
to ensure the highest possible data quality, successful 
recruitment and adherence to the EPAD principles.
The EPAD project does not operate alone. Together 
with IMI’s EMIF-AD, Amyloid imaging to prevent Alzhei-
mer’s disease (AMYPAD), Real world outcomes across 
the AD spectrum for better care: multi-modal data access 
platform (ROADMAP), and Organising Knowledge about 
Neurodegenerative Disease Mechanisms for the Improve-
ment of Drug Development and Therapy (AETIONOMY) 
projects, it forms a key and major part of the IMI-AD plat-
form. It is also working closely with other, similar initiatives 
worldwide, including the US-based Global Alzheimer’s 
Platform. The multinational approach and academia–
industry collaborations are essential for advancing 
knowledge on the entire spectrum of AD and for finding 
effective therapies to prevent the onset of dementia.
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